cookies-img
We use third-party cookies to provide support. By continuing to browse this website, you accept our privacy policy.
close-icon
Aurinia Pharmaceuticals Inc
42 own
64 watching
Current Price
$9.12
$0.16
(1.79%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Market Capitalization
Market Capitalization
1,297.48M
52-Week High
52-Week High
13.415
52-Week Low
52-Week Low
4.07
Average Volume
Average Volume
1.82M
Dividend Yield
Dividend Yield
--
P/E Ratio
P/E Ratio
--
iconMarket Capitalization1,297.48M
icon52-Week High13.415
icon52-Week Low4.07
iconAverage Volume1.82M
iconDividend Yield--
iconP/E Ratio--
What does the Aurinia Pharmaceuticals Inc do?
Aurinia Pharmaceuticals Inc., a biopharmaceutical company, is engaged in the development of a therapeutic drug to treat autoimmune diseases in Canada. The company's lead drug includes Voclosporin, a calcineurin inhibitor for the treatment of lupus nephritis. It has a development and license agreement with 3SBio Inc. for the clinical development, registration, and commercialization of voclosporin in China; and licensing and collaboration agreement with Vifor Pharma for the treatment of lupus and various proteinuric nephrology indications. The company was formerly known as Isotechnika Pharma Inc. and changed its name to Aurinia Pharmaceuticals Inc. in October 2013. Aurinia Pharmaceuticals Inc. was founded in 1993 and is headquartered in Victoria, Canada.
Read More
How much money does Aurinia Pharmaceuticals Inc make?
News & Events about Aurinia Pharmaceuticals Inc.
Business Wire
1month ago
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company) today announced that the Swiss Agency for Therapeutic Products (Swissmedic) has granted marketing authorization of LUPKYNIS (voclosporin) in combination with a background immunosuppressive therapy to treat adults with active class...
Business Wire
1month ago
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company) today announced that Glass Lewis & Co. (Glass Lewis), a leading independent proxy advisor, has recommended that Aurinia shareholders vote FOR ALL proposals at the Companys 2023 Annual General Meeting (the Meeting...
Business Wire
1month ago
Toni Braxton, the award-winning singer, songwriter, actress, producer, and entrepreneur is speaking out about living with lupus and the importance of prioritizing kidney health. In partnership with Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH), a biopharmaceutical company committed to changing the...
Business Wire
1month ago
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company) today announced that the United States Patent and Trademark Office (USPTO) has issued a new and refined method of use patent titled IMPROVED PROTOCOL FOR TREATMENT OF LUPUS NEPHRITIS. Aurinias newly issued U.S. Patent (No...
Zolmax
2 months ago
Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH Get Rating) (TSX:AUP) has earned an average recommendation of Moderate Buy from the six analysts that are currently covering the firm, Marketbeat Ratings reports. Two research analysts have rated the stock with a hold rating and four have assigned a buy ...
Frequently Asked Questions
Frequently Asked Questions
What is Aurinia Pharmaceuticals Inc share price today?
plus_minus_icon
Can Indians buy Aurinia Pharmaceuticals Inc shares?
plus_minus_icon
How can I buy Aurinia Pharmaceuticals Inc shares from India?
plus_minus_icon
Can Fractional shares of Aurinia Pharmaceuticals Inc be purchased?
plus_minus_icon
What are the documents required to start investing in Aurinia Pharmaceuticals Inc stocks?
plus_minus_icon
What is today’s traded volume of Aurinia Pharmaceuticals Inc?
plus_minus_icon
What is today’s market capitalisation of Aurinia Pharmaceuticals Inc?
plus_minus_icon
What is the 52-Week High and Low Range of Aurinia Pharmaceuticals Inc?
plus_minus_icon
What percentage is Aurinia Pharmaceuticals Inc down from its 52-Week High?
plus_minus_icon
What percentage is Aurinia Pharmaceuticals Inc up from its 52-Week Low?
plus_minus_icon
Current Price
$9.12
$0.16
(1.79%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Related Stocks
Kura Oncology Inc
Kura Oncology Inc
$13.50
$0.18 (1.35 %)
ESSA PHARMA INC
ESSA PHARMA INC
$2.99
$-0.01 (-0.33 %)
Vericel Corporation
Vericel Corporation
$32.66
$0.54 (1.68 %)
ADMA BIOLOGICS INC
ADMA BIOLOGICS INC
$4.01
$-0.06 (-1.47 %)
Sign up and dive into a whole new world of investing.
Join over 370,000 who have signed up and are using Stockal successfully already.
Related Stocks
Kura Oncology Inc
Kura Oncology Inc
$13.50
$0.18 (1.35 %)
ESSA PHARMA INC
ESSA PHARMA INC
$2.99
$-0.01 (-0.33 %)
Vericel Corporation
Vericel Corporation
$32.66
$0.54 (1.68 %)
ADMA BIOLOGICS INC
ADMA BIOLOGICS INC
$4.01
$-0.06 (-1.47 %)
Sign up and dive into a whole new world of investing.
Join over 370,000 who have signed up and are using Stockal successfully already.

              Borderless Investing Inc., (“Borderless Investing”), the owner of the Stockal Platform, is not a broker-dealer nor an investment advisor and through its affiliate stockbroker Stockal Securities Pvt. Ltd., (SEBI INZ000301236), acting as the introducing entity has entered into a clearing agreement with DriveWealth LLC., to offer U.S. equities on the Stockal Platform. The Stockal Platform enables investments in a diverse set of global assets from a single account from anywhere in the world. As such, Borderless Investing makes no warranties or representations, express or implied, on products and services offered through its website/platform. It accepts no liability for any damages or losses, however, caused in connection with the use of related services.

              All investments involve risk and returns will fluctuate, are subject to market volatility and may cause losses. The material on this website/platform is provided solely for informational and educational purposes and shall not in any manner be considered a recommendation or endorsement of any strategy or investment, nor an offer to sell or a solicitation of an offer to buy securities, products or services nor advice. Borderless Investing makes no guarantee as to the currency, accuracy, or quality of information published and/or archived on this website/platform, nor will Borderless Investing accept any responsibility for other organizations, businesses, and private persons that provide information on this website/platform. All information on this website/platform regarding products and services provided by Borderless Investing is subject to change without notice. Reasonable efforts are taken to ensure the accuracy and integrity of all information provided here, but Borderless Investing is not responsible for misprints, out of date information, or errors. Any investment decision and/or strategy that investors make or employ, whether or not such decision or strategy derives from or relies upon material accessed or provided through this website/platform, is undertaken at the investor’s sole discretion and risk. Before making any investment decisions, investors should consult additional sources of information and/or their legal or tax advisor. PLEASE READ THIS FULL DISCLOSURE CAREFULLY BEFORE USING THIS SERVICE. BY USING THE SERVICE OR CLICKING AGREE YOU ARE AGREEING TO BE BOUND BY THESE DISCLOSURES AND ALL TERMS AND CONDITIONS ON THIS WEBSITE/PLATFORM.

              *DriveWealth LLC., a member of the Securities Investor Protection Corporation (SIPC), will serve as the custodian for your securities account. In the event that DriveWealth LLC., fails and is placed in liquidation under the Securities Investor Protection Act, securities in your brokerage account may be protected up to $500,000. For details, please see www.sipc.org.

              All brands and logos used on this website are the property of their respective owners.

              Get Started with as little as $1.00